This week's wave of biotech IPO players bumps up offerings and targets bigger harvests of cash

It’s time for the latest round of biotech IPO news, which now focuses on the upsizing process ahead of the pricing.

→ For starters, we have Inozyme Pharma, a preclinical startup out of Boston that is now looking to raise $104 million by selling 6.5 million shares at $16 a pop. As Renaissance Capital notes, they had initially laid out plans to sell 5 million shares at $14 to $16 each.